PEOPLE - Targeted Diagnostics & Therapeutics (TDT) makes appointment:
This article was originally published in Clinica
Targeted Diagnostics & Therapeutics (TDT), developer of molecular-based technologies for the targeted detection, diagnosis and treatment of gastrointestinal cancers and infectious diseases, has appointed Daniel O'Shannessy to the newly-created position of COO. He will be responsible for directing the West Chester, Pennsylvania-based firm's clinical and business expansion, as well as overseeing the strategic growth of new products and technologies. Dr O'Shannessy joins TDT from Gen-Probe, where he served as senior director of strategic planning for the oncology diagnostics division.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.